{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:21:13Z","timestamp":1792005673953,"version":"4.4.0"},"reference-count":166,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Priority Research Center Program","award":["NRF-2021R1A6A1A03038865"],"award-info":[{"award-number":["NRF-2021R1A6A1A03038865"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer has a long disease history and a wide variety and uncertainty in individual patients\u2019 clinical progress. In recent years, we have seen a revolutionary advance in both prostate cancer patient care and in the research field. The power of deep sequencing has provided cistromic and transcriptomic knowledge of prostate cancer that has not discovered before. Our understanding of prostate cancer biology, from bedside and molecular imaging techniques, has also been greatly advanced. It is important that our current theragnostic schemes, including our diagnostic modalities, therapeutic responses, and the drugs available to target non-AR signaling should be improved. This review article discusses the current progress in the understanding of prostate cancer biology and the recent advances in diagnostic and therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms232214257","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T03:29:50Z","timestamp":1668742190000},"page":"14257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Complexities of Prostate Cancer"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-8404","authenticated-orcid":false,"given":"Sobia","family":"Wasim","sequence":"first","affiliation":[{"name":"Department of Neuroscience, College of Medicine, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-8553","authenticated-orcid":false,"given":"Sang-Yoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, College of Medicine, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-1159","authenticated-orcid":false,"given":"Jaehong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e222246","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in Incidence of Metastatic Prostate Cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","article-title":"Prevention and early detection of prostate cancer","volume":"15","author":"Cuzick","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2019). Prostate cancer: A tale of two sides. Nat. Rev. Urol., 16, 141.","DOI":"10.1038\/s41585-019-0152-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41585-018-0020-2","article-title":"Translational models of prostate cancer bone metastasis","volume":"15","author":"Berish","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1200\/JCO.2017.72.8030","article-title":"Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion","volume":"35","author":"Virgo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"i4405","DOI":"10.1136\/bmj.i4405","article-title":"Advances in the management of castration resistant prostate cancer","volume":"355","author":"Ritch","year":"2016","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: Genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","article-title":"Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue","volume":"47","author":"Cooper","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gcc.21944","article-title":"High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer","volume":"51","author":"Boyd","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","article-title":"Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity","volume":"9","author":"Berglund","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_17","first-page":"543","article-title":"Clinical variability and molecular heterogeneity in prostate cancer","volume":"18","author":"Shoag","year":"2016","journal-title":"Asian J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"ref_19","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Investig. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Force","year":"2018","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1078-0432.CCR-15-0941","article-title":"Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening","volume":"22","author":"Auvinen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","article-title":"Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"98","author":"Stephenson","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","article-title":"Cancer control with radical prostatectomy alone in 1,000 consecutive patients","volume":"167","author":"Hull","year":"2002","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-020-0332-z","article-title":"All change in the prostate cancer diagnostic pathway","volume":"17","author":"Lomas","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3348\/kjr.2022.0059","article-title":"Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy","volume":"23","author":"Park","year":"2022","journal-title":"Korean J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apm.12533","article-title":"International Society of Urological Pathology (ISUP) grading of prostate cancer\u2014An ISUP consensus on contemporary grading","volume":"124","author":"Egevad","year":"2016","journal-title":"APMIS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrurol.2016.96","article-title":"Prostate cancer: Urology journals recommend new prostate cancer grade groups","volume":"13","author":"Epstein","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5152\/tud.2018.56056","article-title":"Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions","volume":"44","author":"Demirel","year":"2018","journal-title":"Turk. J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","article-title":"Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole-mount histopathology","volume":"67","author":"Le","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"W87","DOI":"10.2214\/AJR.14.13285","article-title":"Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology","volume":"205","author":"Tan","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging\u2014Reporting and Data System: 2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: Current state of the art and future challenges","volume":"19","author":"Rowe","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","article-title":"The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET\/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_37","first-page":"374","article-title":"Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging","volume":"17","author":"Ghodsirad","year":"2020","journal-title":"Urol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_39","unstructured":"Cancer Genome Atlas Research Network (2015). The Molecular Taxonomy of Primary Prostate Cancer. Cell, 163, 1011\u20131025."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1464-410X.2003.04232.x","article-title":"A systematic review and meta-analysis of familial prostate cancer risk","volume":"91","author":"Johns","year":"2003","journal-title":"BJU Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial Risk and Heritability of Cancer Among Twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1464-410X.2003.04536.x","article-title":"Familial risk of prostate cancer in Iceland","volume":"92","author":"Eldon","year":"2003","journal-title":"BJU Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1\u20133 ng\/ml","volume":"65","author":"Nordstrom","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2012.11648.x","article-title":"Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort","volume":"112","author":"Goh","year":"2013","journal-title":"BJU Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2020.38.15_suppl.1505","article-title":"BARCODE 1: A pilot study investigating the use of genetic profiling to identify men in the general population with the highest risk of prostate cancer to invite for targeted screening","volume":"38","author":"Eeles","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1038\/s41467-021-26489-0","article-title":"Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse","volume":"12","author":"Fraser","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","article-title":"Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus","volume":"174","author":"Gao","year":"2018","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2018.06.014","article-title":"Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19","volume":"174","author":"Hua","year":"2018","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fcell.2020.00347","article-title":"Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs","volume":"8","author":"Zou","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., and Slovin, S. (2017). Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis. Oncol., 2017.","DOI":"10.1200\/PO.17.00029"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cell.2018.10.019","article-title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","volume":"175","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2016.10.013","article-title":"Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors","volume":"72","author":"Lalonde","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/modpathol.2017.166","article-title":"The Genomics of Prostate Cancer: Emerging understanding with technologic advances","volume":"31","author":"Rubin","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","article-title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study","volume":"15","author":"Lalonde","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burden predicts prostate cancer relapse","volume":"111","author":"Hieronymus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mdv004","article-title":"Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes","volume":"26","author":"Mikropoulos","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/ijc.29949","article-title":"Screening for familial and hereditary prostate cancer","volume":"138","author":"Lynch","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","article-title":"A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk","volume":"65","author":"Karlsson","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","article-title":"Genetic aberrations in DNA repair pathways: A cornerstone of precision oncology in prostate cancer","volume":"124","author":"Lozano","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","article-title":"The influence of BRCA2 mutation on localized prostate cancer","volume":"16","author":"Taylor","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pacheco-Barcia, V., Munoz, A., Castro, E., Ballesteros, A.I., Marquina, G., Gonzalez-Diaz, I., Colomer, R., and Romero-Laorden, N. (2022). The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 14.","DOI":"10.3390\/cancers14122950"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e29904","DOI":"10.4161\/mco.29904","article-title":"Chromosomal Rearrangements in Cancer: Detection and potential causal mechanisms","volume":"1","author":"Hasty","year":"2014","journal-title":"Mol. Cell Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.celrep.2014.04.023","article-title":"BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability","volume":"7","author":"Yata","year":"2014","journal-title":"Cell Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J. Cancer"},{"key":"ref_77","first-page":"5037","article-title":"Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2015.109","article-title":"The oncogene ERG: A key factor in prostate cancer","volume":"35","author":"Adamo","year":"2016","journal-title":"Oncogene"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1126\/science.1178124","article-title":"Induced chromosomal proximity and gene fusions in prostate cancer","volume":"326","author":"Mani","year":"2009","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tem.2011.07.006","article-title":"Androgen receptor-driven chromatin looping in prostate cancer","volume":"22","author":"Wu","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/1055-9965.EPI-12-0042","article-title":"The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis","volume":"21","author":"Pettersson","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1593\/neo.06427","article-title":"TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions","volume":"8","author":"Cerveira","year":"2006","journal-title":"Neoplasia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccr.2010.03.018","article-title":"An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression","volume":"17","author":"Yu","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41388-019-0730-9","article-title":"TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells","volume":"38","author":"Zhou","year":"2019","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Semaan, L., Mander, N., Cher, M.L., and Chinni, S.R. (2019). TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6185-0"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1038\/mtna.2016.16","article-title":"Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide","volume":"5","author":"Urbinati","year":"2016","journal-title":"Mol. Nucleic Acids"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hagglof, C., Hammarsten, P., Stromvall, K., Egevad, L., Josefsson, A., Stattin, P., Granfors, T., and Bergh, A. (2014). TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086824"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12935-018-0672-2","article-title":"Predictive significance of TMRPSS2-ERG fusion in prostate cancer: A meta-analysis","volume":"18","author":"Song","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/0008-5472.CAN-08-2467","article-title":"TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy","volume":"69","author":"Gopalan","year":"2009","journal-title":"Cancer Res."},{"key":"ref_92","first-page":"200","article-title":"Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: A large-sample study in Chinese people and a systematic review","volume":"22","author":"Kong","year":"2020","journal-title":"Asian J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pros.21265","article-title":"TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients","volume":"71","author":"Tsusuki","year":"2011","journal-title":"Prostate"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrurol.2017.140","article-title":"Ethnicity and ERG frequency in prostate cancer","volume":"15","author":"Sedarsky","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Tsourlakis, M.C., Stender, A., Quaas, A., Kluth, M., Wittmer, C., Haese, A., Graefen, M., Steurer, S., Simon, R., and Korbel, J. (2016). Heterogeneity of ERG expression in prostate cancer: A large section mapping study of entire prostatectomy specimens from 125 patients. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2674-6"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc3263","article-title":"Pioneer factors in hormone-dependent cancers","volume":"12","author":"Jozwik","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Park, S., Lee, H.Y., Kim, J., Park, H., Ju, Y.S., Kim, E.G., and Kim, J. (2021). Cerebral Cavernous Malformation 1 Determines YAP\/TAZ Signaling-Dependent Metastatic Hallmarks of Prostate Cancer Cells. Cancers, 13.","DOI":"10.3390\/cancers13051125"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.21037\/tau-20-1339","article-title":"Epigenetics in prostate cancer: Clinical implications","volume":"10","author":"Conteduca","year":"2021","journal-title":"Transl. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/iju.14406","article-title":"Epigenetic modifications in prostate cancer","volume":"28","author":"Sugiura","year":"2021","journal-title":"Int. J. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pros.23385","article-title":"Epigenetic risk score improves prostate cancer risk assessment","volume":"77","author":"Groskopf","year":"2017","journal-title":"Prostate"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","article-title":"Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study","volume":"189","author":"Stewart","year":"2013","journal-title":"J. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI130887","article-title":"Genome-wide plasma DNA methylation features of metastatic prostate cancer","volume":"130","author":"Wu","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/pros.23477","article-title":"Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients","volume":"78","author":"Hendriks","year":"2018","journal-title":"Prostate"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/nar\/gkx1306","article-title":"Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer","volume":"46","author":"He","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/JU.0000000000000134","article-title":"Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests","volume":"202","author":"Falagario","year":"2019","journal-title":"J. Urol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e2014674","DOI":"10.1001\/jamanetworkopen.2020.14674","article-title":"Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US","volume":"3","author":"Agrawal","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e1918911","DOI":"10.1001\/jamanetworkopen.2019.18911","article-title":"Trends in the Adoption of Robotic Surgery for Common Surgical Procedures","volume":"3","author":"Sheetz","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(16)30592-X","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study","volume":"388","author":"Yaxley","year":"2016","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2009.1451","article-title":"Comparative effectiveness of minimally invasive vs open radical prostatectomy","volume":"302","author":"Hu","year":"2009","journal-title":"JAMA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.juro.2012.01.061","article-title":"Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States","volume":"187","author":"Lowrance","year":"2012","journal-title":"J. Urol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/d41586-020-01037-w","article-title":"A closer look at a revered robot","volume":"580","author":"Crew","year":"2020","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/0284186X.2010.576115","article-title":"Curative radiation therapy in prostate cancer","volume":"50","author":"Harmenberg","year":"2011","journal-title":"Acta Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajur.2019.02.002","article-title":"Systemic treatment for metastatic prostate cancer","volume":"6","author":"Gravis","year":"2019","journal-title":"Asian J. Urol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Wang, B.R., Chen, Y.A., Kao, W.H., Lai, C.H., Lin, H., and Hsieh, J.T. (2022). Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081872"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.2017.35.6_suppl.173","article-title":"Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy","volume":"35","author":"Posadas","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e000642","DOI":"10.1136\/jitc-2020-000642","article-title":"A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone","volume":"8","author":"Graff","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.1250255","article-title":"Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer","volume":"346","author":"Theurillat","year":"2014","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2015.07.026","article-title":"SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression","volume":"59","author":"Gan","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","article-title":"Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer","volume":"74","author":"Geng","year":"2014","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-021-01397-5","article-title":"SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"109625","DOI":"10.1016\/j.celrep.2021.109625","article-title":"Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity","volume":"36","author":"Grbesa","year":"2021","journal-title":"Cell Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e09207","DOI":"10.7554\/eLife.09207","article-title":"SPOP mutation leads to genomic instability in prostate cancer","volume":"4","author":"Boysen","year":"2015","journal-title":"Elife"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urolonc.2009.03.016","article-title":"Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease","volume":"27","author":"Mostaghel","year":"2009","journal-title":"Urol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 inhibitors\u2013abiraterone, C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Yin","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrurol.2012.175","article-title":"Prostate cancer-from steroid transformations to clinical translation","volume":"9","author":"Chang","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"104576","DOI":"10.1016\/j.isci.2022.104576","article-title":"Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Tsai, H.K., Lehrer, J., Alshalalfa, M., Erho, N., Davicioni, E., and Lotan, T.L. (2017). Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3729-z"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.21037\/tau-20-1131","article-title":"Narrative review of challenges in the management of advanced neuroendocrine prostate cancer","volume":"10","author":"Okasho","year":"2021","journal-title":"Transl. Urol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1038\/modpathol.2017.164","article-title":"Neuroendocrine tumors of the prostate","volume":"31","author":"Fine","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41585-020-0349-1","article-title":"The Movember Prostate Cancer Landscape Analysis: An assessment of unmet research needs","volume":"17","author":"Kouspou","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic Markers in Prostate Cancer Decision Making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrurol.2016.45","article-title":"Active surveillance for prostate cancer: Current evidence and contemporary state of practice","volume":"13","author":"Tosoian","year":"2016","journal-title":"Nat. Rev. Urol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/14257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:20:26Z","timestamp":1760145626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/14257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":166,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232214257"],"URL":"https:\/\/doi.org\/10.3390\/ijms232214257","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}